Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial

NCT04486911 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

89

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Pyrotinib maleate, SHR6390, letrozole

Sponsor

Shengjing Hospital